{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T20:42:38Z","timestamp":1769114558336,"version":"3.49.0"},"reference-count":32,"publisher":"Walter de Gruyter GmbH","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>\n                  <jats:bold>Background<\/jats:bold>: Autoantibodies against \u03b2<jats:sub>1<\/jats:sub>-adrenergic receptors (\u03b2<jats:sub>1<\/jats:sub>AR) that stimulate cardiac cAMP-production play a causal role in the pathogenesis of human heart failure. Patients can be subjected to specific therapies, if the presence of potentially cardio-noxious \u03b2<jats:sub>1<\/jats:sub>AR-autoantibodies is reliably diagnosed. This requires assessment of IgG-interactions with the native \u03b2<jats:sub>1<\/jats:sub>AR because \u03b2<jats:sub>1<\/jats:sub>AR-autoantibodies target a conformational epitope inadequately presented by denatured receptors or linear peptides. Here, we report on a standardised diagnostic procedure for the assessment of \u03b2<jats:sub>1<\/jats:sub>AR-autoantibodies in heart failure patients, which is based on IgG-binding to native human \u03b2<jats:sub>1<\/jats:sub>AR.<\/jats:p>\n               <jats:p>\n                  <jats:bold>Methods: <\/jats:bold>Good laboratory practice (GLP)-conform measurement of \u03b2<jats:sub>1<\/jats:sub>AR-autoantibodies was based on flow-cytometric quantification of differential IgG-binding to native HT1080 cells overexpressing biofluorescent human \u03b2<jats:sub>1<\/jats:sub>AR or not. Receptor-specific IgG-binding was derived from IgG-related median fluorescence of \u03b2<jats:sub>1<\/jats:sub>AR-positive cells corrected for background staining of \u03b2<jats:sub>1<\/jats:sub>AR-negative cells admixed to each measurement. The slope of IgG binding at two different concentrations was used as measure for the titre\/avidity of \u03b21AR-autoantibodies.<\/jats:p>\n               <jats:p>\n                  <jats:bold>Results:<\/jats:bold> Sensitivity and specificity of the novel procedure for high \u03b2<jats:sub>1<\/jats:sub>AR-autoantibody levels in dilated cardiomyopathy patients (n=40, NYHA class III-IV) relative to n=40 matched healthy subjects was &gt;90%. It was similar to functional assays considered the gold standard and vastly superior to existing screening-procedures employing fixed cells or linear receptor-peptides as auto-antigenic targets. Inter-assay scatter was 7%\u201315% and linear dilution recovery was within \u00b110% of expected values throughout.<\/jats:p>\n               <jats:p>\n                  <jats:bold>Conclusions:<\/jats:bold> The novel assay possibly provides a tool to determine true prevalence and clinical impact of \u03b2<jats:sub>1<\/jats:sub>AR-autoantibodies. Furthermore, it may serve as companion diagnostic for therapies specifically directed at \u03b2<jats:sub>1<\/jats:sub>AR-autoantibodies.<\/jats:p>","DOI":"10.1515\/cclm-2015-0603","type":"journal-article","created":{"date-parts":[[2015,9,25]],"date-time":"2015-09-25T08:59:12Z","timestamp":1443171552000},"page":"683-691","source":"Crossref","is-referenced-by-count":9,"title":["A standardised FACS assay based on native, receptor transfected cells for the clinical diagnosis and monitoring of \u03b2<sub>1<\/sub>-adrenergic receptor autoantibodies in human heart disease"],"prefix":"10.1515","volume":"54","author":[{"given":"Beatrice","family":"Bornholz","sequence":"first","affiliation":[{"name":"Institute for Clinical Chemistry and Laboratory Diagnostics, Heinrich Heine University, Medical Faculty, D\u00fcesseldorf, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Benninghaus","sequence":"additional","affiliation":[{"name":"Institute for Clinical Chemistry and Laboratory Diagnostics, Heinrich Heine University, Medical Faculty, D\u00fcesseldorf, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvonne","family":"Reinke","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine B, University Medicine, Greifswald, Germany and DZHK (German Center for Cardiovascular Research), Partner Site Greifswald, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan B.","family":"Felix","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine B, University Medicine, Greifswald, Germany and DZHK (German Center for Cardiovascular Research), Partner Site Greifswald, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Roggenbuck","sequence":"additional","affiliation":[{"name":"Faculty of Natural Sciences, Brandenburg University of Technology, Cottbus-Senftenberg, Germany and GA Generic Assays GmbH and Medipan GmbH, Dahlewitz\/Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Val\u00e9rie","family":"Jahns-Boivin","sequence":"additional","affiliation":[{"name":"Institute of Pharmacology and Toxicology, University of W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland","family":"Jahns","sequence":"additional","affiliation":[{"name":"Comprehensive Heart Failure Center (CHFC) and Interdisciplinary Bank of Biomaterials and Data Wurzburg (ibdw), University Hospital of W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fritz","family":"Boege","sequence":"additional","affiliation":[{"name":"Institute for Clinical Chemistry and Laboratory Diagnostics, Heinrich Heine University, Medical Faculty, D\u00fcesseldorf, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2015,9,25]]},"reference":[{"key":"2024082600032345626_j_cclm-2015-0603_ref_001_w2aab2b8c83b1b7b1ab2ab1Aa","doi-asserted-by":"crossref","unstructured":"Bornholz B, Roggenbuck D, Jahns R, Boege F. Diagnostic and therapeutic aspects of beta-adrenergic receptor autoantibodies in human heart disease. Autoimmun Rev 2014;13:954\u201362.10.1016\/j.autrev.2014.08.021","DOI":"10.1016\/j.autrev.2014.08.021"},{"key":"2024082600032345626_j_cclm-2015-0603_ref_002_w2aab2b8c83b1b7b1ab2ab2Aa","doi-asserted-by":"crossref","unstructured":"Wallukat G, Schimke I. Agonistic autoantibodies directed against g-protein-coupled receptors and their relationship to cardiovascular diseases. Sem Immunopathol 2014;36:351\u201363.10.1007\/s00281-014-0425-9","DOI":"10.1007\/s00281-014-0425-9"},{"key":"2024082600032345626_j_cclm-2015-0603_ref_003_w2aab2b8c83b1b7b1ab2ab3Aa","doi-asserted-by":"crossref","unstructured":"Jahns R, Boivin V, Hein L, Triebel S, Angermann CE, Ertl G, et al. Direct evidence for a beta(1)-adrenergic receptor-directed autoimmune attack as a cause of idiopathic dilated cardiomyopathy. J Clin Invest 2004;113:1419\u201329.10.1172\/JCI200420149","DOI":"10.1172\/JCI200420149"},{"key":"2024082600032345626_j_cclm-2015-0603_ref_004_w2aab2b8c83b1b7b1ab2ab4Aa","doi-asserted-by":"crossref","unstructured":"Jahns R, Boivin V, Lohse MJ. Beta(1)-adrenergic receptor function, autoimmunity, and pathogenesis of dilated cardiomyopathy. Trends Cardiovasc Med 2006;16:20\u20134.10.1016\/j.tcm.2005.11.002","DOI":"10.1016\/j.tcm.2005.11.002"},{"key":"2024082600032345626_j_cclm-2015-0603_ref_005_w2aab2b8c83b1b7b1ab2ab5Aa","doi-asserted-by":"crossref","unstructured":"Stork S, Boivin V, Horf R, Hein L, Lohse MJ, Angermann CE, et al. Stimulating autoantibodies directed against the cardiac beta1-adrenergic receptor predict increased mortality in idiopathic cardiomyopathy. Am Heart J 2006;152:697\u2013704.10.1016\/j.ahj.2006.05.004","DOI":"10.1016\/j.ahj.2006.05.004"},{"key":"2024082600032345626_j_cclm-2015-0603_ref_006_w2aab2b8c83b1b7b1ab2ab6Aa","doi-asserted-by":"crossref","unstructured":"Dandel M, Wallukat G, Potapov E, Hetzer R. Role of beta(1)-adrenoceptor autoantibodies in the pathogenesis of dilated cardiomyopathy. Immunobiol 2012;2017:511\u201320.10.1016\/j.imbio.2011.07.012","DOI":"10.1016\/j.imbio.2011.07.012"},{"key":"2024082600032345626_j_cclm-2015-0603_ref_007_w2aab2b8c83b1b7b1ab2ab7Aa","doi-asserted-by":"crossref","unstructured":"Jahns R, Boivin V, Siegmund C, Inselmann G, Lohse MJ, Boege F. Autoantibodies activating human beta1-adrenergic receptors are associated with reduced cardiac function in chronic heart failure. Circulation 1999;99:649\u201354.10.1161\/01.CIR.99.5.649","DOI":"10.1161\/01.CIR.99.5.649"},{"key":"2024082600032345626_j_cclm-2015-0603_ref_008_w2aab2b8c83b1b7b1ab2ab8Aa","doi-asserted-by":"crossref","unstructured":"Nikolaev VO, Boivin V, Stork S, Angermann CE, Ertl G, Lohse MJ, et al. A novel fluorescence method for the rapid detection of functional beta1-adrenergic receptor autoantibodies in heart failure. J Am Coll Cardiol 2007;50:423\u201331.10.1016\/j.jacc.2007.03.051","DOI":"10.1016\/j.jacc.2007.03.051"},{"key":"2024082600032345626_j_cclm-2015-0603_ref_009_w2aab2b8c83b1b7b1ab2ab9Aa","doi-asserted-by":"crossref","unstructured":"Iwata M, Yoshikawa T, Baba A, Anzai T, Mitamura H, Ogawa S. Autoantibodies against the second extracellular loop of beta(1)-adrenergic receptors predict ventricular tachycardia and sudden death in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 2001;37:418\u201324.10.1016\/S0735-1097(00)01109-8","DOI":"10.1016\/S0735-1097(00)01109-8"},{"key":"2024082600032345626_j_cclm-2015-0603_ref_010_w2aab2b8c83b1b7b1ab2ac10Aa","doi-asserted-by":"crossref","unstructured":"Jahns R, Boivin V, Siegmund C, Boege F, Lohse MJ, Inselmann G. Activating beta-1-adrenoceptor antibodies are not associated with cardiomyopathies secondary to valvular or hypertensive heart disease. J Am Coll Cardiol 1999;34:1545\u201351.10.1016\/S0735-1097(99)00381-2","DOI":"10.1016\/S0735-1097(99)00381-2"},{"key":"2024082600032345626_j_cclm-2015-0603_ref_011_w2aab2b8c83b1b7b1ab2ac11Aa","doi-asserted-by":"crossref","unstructured":"Liu HR, Zhao RR, Zhi JM, Wu BW, Fu ML. Screening of serum autoantibodies to cardiac beta1-adrenoceptors and m2-muscarinic acetylcholine receptors in 408 healthy subjects of varying ages. Autoimmunity 1999;29:43\u201351.10.3109\/08916939908995971","DOI":"10.3109\/08916939908995971"},{"key":"2024082600032345626_j_cclm-2015-0603_ref_012_w2aab2b8c83b1b7b1ab2ac12Aa","doi-asserted-by":"crossref","unstructured":"Bornholz B, Weidtkamp-Peters S, Schmitmeier S, Seidel CA, Herda LR, Felix SB, et al. Impact of human autoantibodies on beta1-adrenergic receptor conformation, activity, and internalization. Cardiovasc Res 2013;97:472\u201380.10.1093\/cvr\/cvs350","DOI":"10.1093\/cvr\/cvs350"},{"key":"2024082600032345626_j_cclm-2015-0603_ref_013_w2aab2b8c83b1b7b1ab2ac13Aa","doi-asserted-by":"crossref","unstructured":"Wallukat G, Nisson E. Anti beta(1)-adrenoceptor autoantibodies analyzed in spontaneously beating neonatal rat heart myocyte cultures \u2013 comparison of methods. Dev Biol 2001;37:175\u20136.","DOI":"10.1290\/1071-2690(2001)037<0175:AAAAIS>2.0.CO;2"},{"key":"2024082600032345626_j_cclm-2015-0603_ref_014_w2aab2b8c83b1b7b1ab2ac14Aa","doi-asserted-by":"crossref","unstructured":"Patel PA, Hernandez AF. Targeting anti-beta-1-adrenergic receptor antibodies for dilated cardiomyopathy. Eur J Heart Fail 2013;15:724\u20139.10.1093\/eurjhf\/hft065","DOI":"10.1093\/eurjhf\/hft065"},{"key":"2024082600032345626_j_cclm-2015-0603_ref_015_w2aab2b8c83b1b7b1ab2ac15Aa","doi-asserted-by":"crossref","unstructured":"Dandel M, Wallukat G, Englert A, Hetzer R. Immunoadsorption therapy for dilated cardiomyopathy and pulmonary arterial hypertension. Atherosclerosis Suppl 2013;14:203\u201311.10.1016\/j.atherosclerosissup.2012.10.029","DOI":"10.1016\/j.atherosclerosissup.2012.10.029"},{"key":"2024082600032345626_j_cclm-2015-0603_ref_016_w2aab2b8c83b1b7b1ab2ac16Aa","doi-asserted-by":"crossref","unstructured":"Felix SB, Staudt A, Landsberger M, Grosse Y, Stangl V, Spielhagen T, et al. Removal of cardiodepressant antibodies in dilated cardiomyopathy by immunoadsorption. J Am Coll Cardiol 2002;39:646\u201352.10.1016\/S0735-1097(01)01794-6","DOI":"10.1016\/S0735-1097(01)01794-6"},{"key":"2024082600032345626_j_cclm-2015-0603_ref_017_w2aab2b8c83b1b7b1ab2ac17Aa","doi-asserted-by":"crossref","unstructured":"Haberland A, Wallukat G, Dahmen C, Kage A, Schimke I. Aptamer neutralization of beta1-adrenoceptor autoantibodies isolated from patients with cardiomyopathies. Circ Res 2011;109:986\u201392.10.1161\/CIRCRESAHA.111.25384921868696","DOI":"10.1161\/CIRCRESAHA.111.253849"},{"key":"2024082600032345626_j_cclm-2015-0603_ref_018_w2aab2b8c83b1b7b1ab2ac18Aa","doi-asserted-by":"crossref","unstructured":"Munch G, Boivin-Jahns V, Holthoff HP, Adler K, Lappo M, Truol S, et al. Administration of the cyclic peptide cor-1 in humans (phase i study): Ex vivo measurements of anti-beta1-adrenergic receptor antibody neutralization and of immune parameters. Eur J Heart Fail 2012;14:1230\u20139.10.1093\/eurjhf\/hfs11822968742","DOI":"10.1093\/eurjhf\/hfs118"},{"key":"2024082600032345626_j_cclm-2015-0603_ref_019_w2aab2b8c83b1b7b1ab2ac19Aa","doi-asserted-by":"crossref","unstructured":"Haberland A, Wallukat G, Berg S, Schulz AM, Freyse EJ, Vetter R, et al. Neutralization of pathogenic beta1-receptor autoantibodies by aptamers in vivo: the first successful proof of principle in spontaneously hypertensive rats. Mol Cell Biol 2014;393:177\u201380.10.1007\/s11010-014-2057-824744110","DOI":"10.1007\/s11010-014-2057-8"},{"key":"2024082600032345626_j_cclm-2015-0603_ref_020_w2aab2b8c83b1b7b1ab2ac20Aa","doi-asserted-by":"crossref","unstructured":"Boivin V, Beyersdorf N, Palm D, Nikolaev VO, Schlipp A, Muller J, et al. Novel receptor-derived cyclopeptides to treat heart failure caused by anti-beta1-adrenoceptor antibodies in a human-analogous rat model. PLoS One 2015;10:e0117589.10.1371\/journal.pone.0117589433633125700031","DOI":"10.1371\/journal.pone.0117589"},{"key":"2024082600032345626_j_cclm-2015-0603_ref_021_w2aab2b8c83b1b7b1ab2ac21Aa","doi-asserted-by":"crossref","unstructured":"Cherezov V, Rosenbaum DM, Hanson MA, Rasmussen SG, Thian FS, Kobilka TS, et al. High-resolution crystal structure of an engineered human beta2-adrenergic g protein-coupled receptor. Science 2007;318:1258\u201365.10.1126\/science.1150577258310317962520","DOI":"10.1126\/science.1150577"},{"key":"2024082600032345626_j_cclm-2015-0603_ref_022_w2aab2b8c83b1b7b1ab2ac22Aa","doi-asserted-by":"crossref","unstructured":"Jahns R, Boivin V, Krapf T, Wallukat G, Boege F, Lohse MJ. Modulation of beta(1)-adrenoceptor activity by domain-specific antibodies and-heart failure-associated autoantibodies. J Am Coll Cardiol 2000;36:1280\u20137.10.1016\/S0735-1097(00)00881-0","DOI":"10.1016\/S0735-1097(00)00881-0"},{"key":"2024082600032345626_j_cclm-2015-0603_ref_023_w2aab2b8c83b1b7b1ab2ac23Aa","doi-asserted-by":"crossref","unstructured":"Jahns R, Boege F. Questionable validity of petide-based elisa strategies in the diagnostics of cadrdiopathogenic autoantibodies that activate g-protein-coupled receptors. Cardiology 2015;131:149\u201350.10.1159\/00037654625926265","DOI":"10.1159\/000376546"},{"key":"2024082600032345626_j_cclm-2015-0603_ref_024_w2aab2b8c83b1b7b1ab2ac24Aa","doi-asserted-by":"crossref","unstructured":"Jahns R, Schlipp A, Boivin V, Lohse MJ. Targeting receptor antibodies in immune cardiomyopathy. Semin Thromb Hemost 2010;36:212\u20138.10.1055\/s-0030-125150620414837","DOI":"10.1055\/s-0030-1251506"},{"key":"2024082600032345626_j_cclm-2015-0603_ref_025_w2aab2b8c83b1b7b1ab2ac25Aa","unstructured":"Hohensinner PJ, Goronzy JJ, Weyand CM. Telomere dysfunction, autoimmunity and aging. Aging Dis 2011;2:524\u201337."},{"key":"2024082600032345626_j_cclm-2015-0603_ref_026_w2aab2b8c83b1b7b1ab2ac26Aa","doi-asserted-by":"crossref","unstructured":"Pei J, Li N, Chen J, Li X, Zhang Y, Wang Z, et al. The predictive values of beta1-adrenergic and m2 muscarinic receptor autoantibodies for sudden cardiac death in patients with chronic heart failure. Eur J Heart Fail 2012;14:887\u201394.10.1093\/eurjhf\/hfs08222713286","DOI":"10.1093\/eurjhf\/hfs082"},{"key":"2024082600032345626_j_cclm-2015-0603_ref_027_w2aab2b8c83b1b7b1ab2ac27Aa","doi-asserted-by":"crossref","unstructured":"Holthoff HP, Zeibig S, Boivin V, Bauer J, Lohse MJ, Kaab S, et al. Detection of anti beta1-ar auto-antibodies in heart failure by a cell-based competition elisa. Circ Res 2012;111:675\u201384.10.1161\/CIRCRESAHA.112.27268222811559","DOI":"10.1161\/CIRCRESAHA.112.272682"},{"key":"2024082600032345626_j_cclm-2015-0603_ref_028_w2aab2b8c83b1b7b1ab2ac28Aa","doi-asserted-by":"crossref","unstructured":"Christ T, Adolph E, Schindelhauer S, Wettwer E, Dobrev D, Wallukat G, et al. Effects of immunoglobulin g from patients with dilated cardiomyopathy on rat cardiomyocytes. Basic Clin Pharmacol Toxicol 2005;96:445\u201352.10.1111\/j.1742-7843.2005.pto_96607.x","DOI":"10.1111\/j.1742-7843.2005.pto_96607.x"},{"key":"2024082600032345626_j_cclm-2015-0603_ref_029_w2aab2b8c83b1b7b1ab2ac29Aa","doi-asserted-by":"crossref","unstructured":"Eckerle LG, Felix SB, Herda LR. Measurement of antibody effects on cellular function of isolated cardiomyocytes. J Vis Exp 2013;e4237.10.3791\/4237362210223524642","DOI":"10.3791\/4237"},{"key":"2024082600032345626_j_cclm-2015-0603_ref_030_w2aab2b8c83b1b7b1ab2ac30Aa","doi-asserted-by":"crossref","unstructured":"Lytton SD, Kahaly GJ. Bioassays for tsh-receptor autoantibodies: an update. Autoimmun Rev 2010;10:116\u201322.10.1016\/j.autrev.2010.08.01820807591","DOI":"10.1016\/j.autrev.2010.08.018"},{"key":"2024082600032345626_j_cclm-2015-0603_ref_031_w2aab2b8c83b1b7b1ab2ac31Aa","doi-asserted-by":"crossref","unstructured":"Roggenbuck D, Hiemann R, Bogdanos D, Reinhold D, Conrad K. Standardization of automated interpretation of immunofluorescence tests. Clin Chim Acta 2013;421:168\u20139.10.1016\/j.cca.2013.03.01923537734","DOI":"10.1016\/j.cca.2013.03.019"},{"key":"2024082600032345626_j_cclm-2015-0603_ref_032_w2aab2b8c83b1b7b1ab2ac32Aa","doi-asserted-by":"crossref","unstructured":"Deubner N, Berliner D, Schlipp A, Gelbrich G, Caforio AL, Felix SB, et al. Cardiac beta1-adrenoceptor autoantibodies in human heart disease: rationale and design of the etiology, titre-course, and survival (etics) study. Eur J Heart Fail 2010;12:753\u201362.10.1093\/eurjhf\/hfq07220494925","DOI":"10.1093\/eurjhf\/hfq072"}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2015-0603\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2015-0603\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T00:03:39Z","timestamp":1724630619000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2015-0603\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,25]]},"references-count":32,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2015,9,25]]},"published-print":{"date-parts":[[2016,4,1]]}},"alternative-id":["10.1515\/cclm-2015-0603"],"URL":"https:\/\/doi.org\/10.1515\/cclm-2015-0603","relation":{},"ISSN":["1437-4331","1434-6621"],"issn-type":[{"value":"1437-4331","type":"electronic"},{"value":"1434-6621","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9,25]]}}}